141290-59-7

Basic information

• Product Name: 1H-INDAZOLE-6-CARBONITRILE
• Synonyms: 1H-INDAZOLE-6-CARBONITRILE;1H-Indazole-6-carbonitrile(9CI);6-Cyano-1H-indazole;6-Cyano Indazole;1H-indazol-6-carbonitrile;6-Cyano-1H-indazole 95%
• CAS NO: 141290-59-7
• Molecular Formula: C₈H₅N₃
• Molecular Weight: 143.15
• Product Categories: NITRILE;Building Blocks;Indazole;Chemical Synthesis;Heterocyclic Building Blocks;Indazoles
• Mol File: 141290-59-7.mol

Chemical Properties

• Melting Point: 128-135℃
• Boiling Point: 370.312°C at 760 mmHg
• Flash Point: 126.669°C
• Appearance: /
• Density: 1.34g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.685
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.61±0.40(Predicted)
• CAS DataBase Reference: 1H-INDAZOLE-6-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-INDAZOLE-6-CARBONITRILE(141290-59-7)
• EPA Substance Registry System: 1H-INDAZOLE-6-CARBONITRILE(141290-59-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 141290-59-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Indazole-6-carbonitrile is used as a key intermediate in the synthesis of various bioactive molecules and pharmaceutical drugs. Its presence in the molecular structure of these compounds contributes to their therapeutic effects, making it an essential component in drug development.
Used in Organic Synthesis:
1H-Indazole-6-carbonitrile is used as a building block in organic synthesis for the creation of diverse chemical structures. Its versatility in forming different molecular configurations allows for the development of a wide range of chemical compounds with various applications.
Used in Research and Development:
1H-Indazole-6-carbonitrile is employed in research and development settings to explore its potential biological activities and applications. Its unique structural properties make it a promising candidate for further investigation into its possible uses in various fields, including medicine and materials science.

InChI:InChI=1/C8H5N3/c9-4-6-1-2-7-5-10-11-8(7)3-6/h1-3,5H,(H,10,11)

Upstream product

• 60710-80-7 5-cyano-2-methylaniline 
• 79762-54-2 6-bromo-1H-indazole 
• 557-21-1 zinc(II) cyanide 
• 267413-32-1 3-amino-6-cyanoindazole 

Downstream Products

• 903557-09-5 C₁₆H₁₁N₃O₂ 
• 1361332-18-4 3-(4-methoxyphenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-6-carbonitrile 
• 1620816-69-4 1-methyl-3,7-diphenyl-1H-indazole-6-carbonitrile 
• 267413-29-6 1-methyl-1H-indazole-6-carbonitrile 
• 1086392-14-4 6-(methylamino)indazole 
• 710943-26-3 (1H-indazol-6-yl)methanamine 
• 885279-07-2 methyl 6-cyano-1H-indazole-3-carboxylate 
• 906000-44-0 1H-indazole-6-carboxamide 
• 704-91-6 1H-indazole-6-carboxylic acid 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold

A novel series of 3-(pyrrolopyridin-2-yl)indazole derivatives were synthesized and biologically evaluated for their anti-proliferative effects on five human cancer cell lines. As a result, all of them exhibited vigorous potency against HL60 cell line with IC50 values ranging from singe digital nanomolar to micromolar level. Besides, a majority of them displayed modest to good antiproliferative activities against the other four cell lines, including KB, SMMC-7721, HCT116, and A549. Particularly, compound 2y, as the most distinguished one in this series, demonstrated IC50 values of 8.3 nM and 1.3 nM against HL60 and HCT116 cell lines, respectively. Afterwards, for exploring the molecular target, compounds2d, 2g and 2y were further selected to evaluate the inhibitory activities against a panel of kinases. Finally, they were identified to be targeting Aurora A kinase with significant selectivity over other kinases, such as CHK1, CDK2, MEK1, GSK3β, BRAF, IKKβ and PKC.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over- activation of NF-kB signaling is observed.

HETERO COMPOUND

[Problems] To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1P1 a

IDENTIFICATION OF COMPOUNDS SUITABLE FOR TREATING AD

The invention provides a method of screening for compounds which inhibit the hyperphosphorylation of tau, and hence are suitable for treating AD and related conditions.

THROMBIN INHIBITORS

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is N Y 1 or O; c is CY 2 or N; d is CY 2; e is CY 1 or N; f is CY 1 or N; g is CY 1 or N; Y 1 is hydrogen, C 1-4 alkyl, or halogen; Y 2 is hydrogen, C 1-4 alkyl, C 3-7 cycloalkyl, halogen, NH 2, OH or C 1-4 alkoxy;A is and W, X, Z, R 3, R 4 and R 5 are defined in the specification.